Dr Lalchandani Labs Ltd.
Snapshot View

View in App

Prices View details >>

31.45 +1.45 ▲4.8%

30 January 2023, 04:01:00 PM
Volume: 12,000

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.lalchandanipathlab.com
Market Cap 13.63 Cr.
Enterprise Value(EV) 15.24 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 2.15 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) 14.60 Trailing Twelve Months Ending 2022-03
Industry PE 46.72 Trailing Twelve Months Ending 2022-03
Book Value / Share 23.90 Trailing Twelve Months Ending 2022-03
Price to Book Value 1.32 Calculated using Price: 31.45
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 0.43 Cr. 4,333,068 Shares
FaceValue 10
Company Profile
They are a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through their integrated network, they offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+4.83%
1 Week
+4.83%
1 Month
+14.36%
3 Month
-3.97%
6 Month
+32.14%
1 Year
-23.20%
2 Year
+121.48%
5 Year
10 Year

Ratios View Details >>

5 years 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 8.11 9.85 6.01 11.56 9.49
Return on Capital Employed (%) 10.06 12.57 9.17 14.88 13.07
Return on Assets (%) 4.23 6.53 4.30 7.46 5.60

Balance Sheet View Details >>

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 3 8 9 10 10
Non Curr. Liab. 1 1 2 3 3
Curr. Liab. 2 1 2 3 5
Minority Int.
Equity & Liab. 6 10 12 15 18
Non Curr. Assets 2 4 4 6 7
Curr. Assets 4 6 8 9 11
Misc. Exp. not W/O 0 0 0 0 0
Total Assets 6 10 12 15 18

Profit Loss View Details >>

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Net Sales 3 5 6 10 11
Other Income 0 0
Total Income 3 5 6 10 11
Total Expenditure -2 -4 -5 -8 -9
PBIDT 1 1 1 2 2
Interest 0 0 0 0 -1
Depreciation 0 0 0 -1 -1
Taxation 0 0 0 0 0
Exceptional Items
PAT 0 1 0 1 1
Adjusted EPS 1 1 1 2 2

Cash Flow View Details >>

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 1 0 0 1 2
Cash Fr. Inv. -1 -2 -1 -2 -2
Cash Fr. Finan. 2 4 1 2 0
Net Change 1 1 0 1 1
Cash & Cash Eqvt 1 2 2 3 4

Shareholding Pattern View Details >>

9 Qtrs 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%) 2021-09 (%) 2022-03 (%) 2022-09 (%)
Promoter 60.78 60.78 60.78 60.78 60.78 60.78 60.78 60.78 60.78
Public 39.22 39.22 39.22 39.22 39.22 39.22 39.22 39.22 39.22
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Tue, 29 Nov 2022
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Wed, 23 Nov 2022
Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Arjan Lachandani
Designation :- Managing Director / Whole Time Director
Mon, 14 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting
We are hereby submitting the Unaudited Financial Results along with Limited Review Report for the half year ended on 30th September 2022.1. Un-audited Financial Results for the half year ended on 30th September 2022.2. Un-audited Statement of Assets and Liabilities for the half year ended on 30th September 2022.3. Cash Flow Statement for the half year ended on 30th September 2022.4. Limited Review Report for the half year ended 30th September 2022.

Technical Scans View Details >>

Mon, 30 Jan 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Opening at High Opening at High
Opening at Low Opening at Low

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 252,338.06 1,051.70 +0.8%
Divi's Laboratories Ltd. 89,367.34 3,366.40 -0.6%
Cipla Ltd. 83,741.18 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. 72,084.75 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. 61,094.10 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. 52,291.51 1,545.05 +0.5%
Abbott India Ltd. 44,555.01 20,967.75 -1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 61.43 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-09 29.89 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-12 31.74 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.79 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.76 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.93 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-09 50.53 20,967.75 -1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.75 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-09 7.37 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-12 3.69 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.28 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.21 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.20 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-09 16.41 20,967.75 -1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 0.04 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 0.00 20,967.75 -1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 29.95 20,967.75 -1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 13.10 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 29.95 20,967.75 -1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,967.75 -1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,051.70 +0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,366.40 -0.6%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,037.50 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,328.80 +0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,249.00 +0.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,545.05 +0.5%
Abbott India Ltd. Standalone 2022-03 798.70 20,967.75 -1.2%

FAQ's On Dr Lalchandani Labs Ltd.

What is Dr Lalchandani Labs share price?
Can I buy Dr Lalchandani Labs shares now?
What is the Market Cap of Dr Lalchandani Labs?
What are the key metrics to analyse Dr Lalchandani Labs?
What is the 52 Week High and Low of Dr Lalchandani Labs?
What is the trend of Dr Lalchandani Labs share price?